Patient Born with Insensitivity to Pain Acquires Neuropathic Pain Following Childbirth

A medical case report of a female patient who had felt no pain since childhood but who, following childbirth, was left with a variety of pain symptoms, has given insights into the manifestation of neuropathic pain. The clinicians involved, Professor Geoff Woods and colleagues from Cambridge University Hospitals, also claim that their findings reveal a great deal about the subjective nature of pain.

Cambridge, United Kingdom, August 26, 2015 --( The report, published on F1000Research and titled Neuropathic pain in a patient with congenital insensitivity to pain ( has just passed peer review. It concerns a unique case of a woman with Channelopathy-associated Insensitivity to Pain (CIP) Syndrome, who developed features of neuropathic pain after sustaining pelvic fractures and an epidural hematoma that impinged on the right fifth lumbar (L5) nerve root. These injuries were sustained during a painless labour, which culminated in a Caesarean section.

The patient had been diagnosed with CIP as child. This was later confirmed by tests showing bi-allelic mutations in the gene that codes for the voltage-gated sodium channel Nav1.7, a protein considered necessary for the sensation of pain. Testing two months after childbirth showed that her ability to sense mechanical stimulation of her feet had increased more than 10-fold compared with tests performed before her pregnancy. However, the authors note that the value of verbal descriptors is somewhat limited in a person who has never felt pain before.

She now suffers from continuous, unpleasant, buzzing sensations and electric shocks in her legs and a vice-like squeezing in the pelvis when she walks. Even though she has not reported sharp, stabbing or burning sensations, her symptoms fall under the International Association for the Study of Pain definition of pain, and she frequently used terms such as ‘hurt’, ‘cramp’ and ‘aching’.

Professor Woods and his colleagues state: “The Nav1.7 channel plays a crucial role in pain transmission; however, this case shows that neuropathic pain can be initiated and maintained in its absence in humans, as well as in knockout mice. Our data provides a further basis for seeking specific molecular substrates for neuropathic pain, some of which could act as mechanistic targets for new therapies for patients with such symptoms.”

This case shows that, contrary to popular belief, pain (or at least a form of it) can be induced in humans without Nav1.7 channels. This finding raises the possibility that pain-killers developed to target this channel may only be able to relieve certain aspects of neuropathic pain.

Rebecca Lawrence, Managing Director of F1000Research, said: “This fascinating case report represents important work in the field of pain transmission and ultimately, management. Through F1000Research, the authors have been able to share their findings immediately, and with the widest audience.”

For more information:

Catherine McNulty or Andrew Baud, Tala (on behalf of F1000 Research), +44 (0) 20 3397 3383 or +44 (0) 7775 715775

About F1000Research

F1000Research is an open science publishing platform for life scientists that offers immediate publication and transparent peer review, avoiding editorial bias and ensuring the inclusion of all source data. This process helps scientists to avoid the traditional, anonymous, pre-publication peer-review process that can cause long delays before new results become visible.

All articles must pass an initial in-house quality check prior to publication on F1000Research. Following open, invited peer review where the referee’s name and affiliation and the referee reports are published alongside the article, authors can make revisions that are then published as new article versions.

Since its launch in January 2013, F1000Research has published more than 900 articles across the life sciences, written by more than 3,000 authors. For more details on F1000Research go to

About Cambridge University Hospitals (CUH)

Cambridge University Hospitals (CUH) is one of the largest and best known hospitals in the country. As well as delivering care through Addenbrooke’s and the Rosie, it is also:

a leading national centre for specialist treatment for rare or complex conditions
a government-designated biomedical research centre
one of only five academic health science centres in the UK
a university teaching hospital with a worldwide reputation
a partner in the development of the Cambridge Biomedical Campus

CUH’s vision is to be one of the best academic healthcare organisations in the world.

For further information, please contact Adrian Ient, Senior Media Relations Manager, Communications Department, Cambridge University Hospitals, Hills Road, Cambridge CB2 0QQ, Tel: 01223 274433, Email:
Faculty of 1000
Harriet Mountford
0203 397 3383